Cancer
Blood cancer drug Adcetris approved by FDA
August 24, 2011Sales and Marketing Adcetris, Cancer, Seattle Genetics, lymphoma
The FDA has approved Seattle Genetics’ blood cancer drug Adcetris for two forms of lymphoma. Adcetris (brentuximab vedotin) can now …
EMA to review two new Pfizer cancer drugs
August 19, 2011Sales and Marketing Cancer, Pfizer, bosutinib, crizotinib
The EMA has accepted Pfizer’s regulatory submissions for two of its new cancer compounds. The first is its much-lauded crizotinib, …
Roche cancer drug Tarceva set for first-line licence
July 25, 2011Sales and Marketing Cancer, Roche, Tarceva
Roche’s cancer drug Tarceva is on course to win a first-line indication in Europe for the first time after regulatory …
Afinitor poised to realise blockbuster ambitions?
July 25, 2011Sales and Marketing Afinitor, Cancer, Novartis
Novartis’ Afinitor may be set to make good on its blockbuster promise after receiving European backing for its second licence …
ASCO 2011: news from the front line against cancer
July 18, 2011Research and Development ASCO, Cancer, oncology
Pharmafocus presents selected highlights from the American Society of Clinical Oncology’s annual meeting in Chicago, beginning with non-small cell lung …
Amgen collaborates on cancer antibody research
July 13, 2011Research and Development Amgen, Cancer, TGF-beta monoclonal antibody, research and development news
Amgen has teamed up with German biotech Micromet to develop tumour-destroying antibodies in a two-year deal that could net Micromet …
BMS licences potential first-in-class cancer biologic
July 7, 2011Research and Development BMS, Cancer, biologics
Bristol-Myers Squibb has signed a $465 million deal for the rights to a potential first-in-class treatment for cancer. IPH2102 is …
Mid-stage trial boost for Roche skin cancer drug vismodegib
June 20, 2011Research and Development Cancer, Roche, skin cancer, vismodegib
Roche’s novel skin cancer drug vismodegib has met its primary endpoint in a phase II trial. Vismodegib is an investigational, …
NHS failed to use extra cancer drug funds
June 17, 2011Sales and Marketing Cancer, Cancer Drugs Fund, Erbitux, avastin
The million pound fund set up to increase NHS uptake of new cancer drugs was widely underused, with just over …
Daiichi Sankyo: Europe poses huge challenge for pharma
June 9, 2011Research and Development, Sales and Marketing Cancer, Daiichi Sankyo, pricing
Japanese pharma company Daiichi Sankyo is expanding its European operations, creating a new oncology business unit. But outlining its plans …
Lansley announces U-turn on cancer networks
May 23, 2011Cancer, NHS, NHS reforms
Health secretary Andrew Lansley has declared that cancer networks will be maintained, reversing an earlier decision to axe them. Lansley …
Blood cancer charity to kick-start clinical trials
May 19, 2011Research and Development Cancer, blood cancer, clinical trials, leukaemia
A UK blood cancer charity is creating a network of clinical trial centres with backing from the NIHR Clinical Research …
GSK withdraws applications for Avodart
March 25, 2011Research and Development Avodart, Cancer, GSK, bph, prostate cancer
GlaxoSmithKline has withdrawn all regulatory applications for Avodart to prevent prostate cancer after regulators raised doubts about its benefit/risk profile. …
Eisai marine sponge derived cancer drug approved in Europe
March 23, 2011Sales and Marketing Cancer, Eisai, Halaven, Halichondria okadai, breast cancer, eribulin mesylate
Eisai’s injectible breast cancer drug Halaven has been approved by European regulators. The highly novel drug is made from a …
Dendreon wins green light for Provenge production
March 22, 2011Manufacturing and Production Cancer, Dendreon, FDA, Provenge, pharma manufacturing, prostate cancer vaccine, sipuleucel-T
US oncology specialist Dendreon has been boosted by the approval of additional production capacity for its therapeutic prostate cancer vaccine …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
